We are a development stage biopharmaceutical company focused on infectious disease and dermatology. We have two base technology platforms each with multiple applications: Ceragenins (also known as cationic steroid antibiotics or "CSAs") and barrier repair ("Barrier Repair"). We believe that the Barrier Repair platform represents near term revenue opportunities for prescription skin care products to treat a variety of skin disorders all characterized by a disrupted skin barrier. Our Ceragenin technology has shown antibiotic, antiviral, anti-fungal and anti cancer properties in vitro and represents a mid and long term revenue opportunity both in antimicrobial medical device coating applications and in new prescription antimicrobial drug development.
compounds are electrostatically attracted to bacteria, viruses, and certain lines of cancer that all share in common the presence of negatively charged phospholipids on their cell membrane surfaces. The compounds are believed to primarily act via induction of apoptosis by rapid depolarization of the cell membranes (tear holes in the cell walls). Unlike most antibiotics which are bacteriastatic (prevents the reproduction of bacteria cells), the CerageninsOur Ceragenin technology, licensed from Brigham Young University, covers the composition of matter and use of a broad class of small molecule, positively charged aminosterol compounds that have shown antibiotic, antiviral, antifungal, and anticancer activity. These patented compounds mimic the activity of the naturally occurring antimicrobial peptides that form the body's innate immune system and several of these candidates are currently in pre-clinical development. Ceragenin are bacteriacidal (kills the bacterial cells). Other efforts to duplicate the naturally occurring antimicrobial peptides have proven not to be commercially viable because of the inability to stabilize and cost effectively produce bulk quantities of such compounds. Ceragenins, however, are neither peptides nor steroids, but rather cationic steroid shaped small molecules that we believe are far simpler, more stable and inexpensive to produce in bulk quantities.
compounds are electrostatically attracted to bacteria, viruses, and certain lines of cancer that all share in common the presence of negatively charged phospholipids on their cell membrane surfaces. The compounds are believed to primarily act via induction of apoptosis by rapid depolarization of the cell membranes (tear holes in the cell walls). Unlike most antibiotics which are bacteriastatic (prevents the reproduction of bacteria cells), the CerageninsOur Ceragenin technology, licensed from Brigham Young University, covers the composition of matter and use of a broad class of small molecule, positively charged aminosterol compounds that have shown antibiotic, antiviral, antifungal, and anticancer activity. These patented compounds mimic the activity of the naturally occurring antimicrobial peptides that form the body's innate immune system and several of these candidates are currently in pre-clinical development. Ceragenin are bacteriacidal (kills the bacterial cells). Other efforts to duplicate the naturally occurring antimicrobial peptides have proven not to be commercially viable because of the inability to stabilize and cost effectively produce bulk quantities of such compounds. Ceragenins, however, are neither peptides nor steroids, but rather cationic steroid shaped small molecules that we believe are far simpler, more stable and inexpensive to produce in bulk quantities.
